Clinical Trial Update: Molecular Cerebral Imaging in Incipient Dementia (MCI-ID) II [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial on molecular cerebral imaging for incipient dementia in mild cognitive impairment was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Snippet

Sponsor: University of California, Los Angeles | Conditions: Mild Cognitive Impairment | Phase 3 | Status: WITHDRAWN